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Abstract
The present study investigated the role of first use of inhalants within a first drug sequencing 
pattern. In a representative sample of university students from 27 Brazilian capitals (n=12,711), 
we analyzed the patterns of transition from/to first use of inhalants to/from the first use of alcohol, 
tobacco, cannabis, cocaine, hallucinogens, ecstasy, amphetamines, prescription opioids, and 
tranquilizers. Cox proportional hazards models were used to analyze data. Drugs that were not 
specified as the pair of drugs tested in each model were included as time-varying covariates in all 
models. In this sample, first use of inhalants was preceded only by the first use of alcohol and 
tobacco. However, first use of inhalants preceded first use of cannabis, amphetamines, cocaine, 
and tranquilizers. First use of inhalants preceded the first use of prescription opioids, and vice 
versa. This study highlights the need to intervene early with youths who are at risk of or just 
beginning to use inhalants, since this class of drugs seems to be the first illegal drug in Brazil to be 
experimented by respondents in our sample. There is also a call for attention to individuals who 
have already first used inhalants because of their higher chance to experiment with other drugs 
such as cannabis, cocaine, and prescription drugs. All these findings show an in-transition culture 
of drug use, which should be tracked through the time, since some classical models (i.e., gateway 
model) might be outdated and might also not fit within different settings.
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1. Introduction
Inhalants are one of the most popular drug classes throughout the world. Inhalant abuse, 
which is also referred to as volatile substance abuse or solvent abuse, is a worldwide 
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problem with major consequences for abusers, their families and society (Balster et al., 
2009), yet it is one of the least-understood and poorly studied substance abuse problems 
(Balster et al., 2009). Despite the substantial prevalence and serious toxicities of inhalant 
use, it has been termed “the forgotten epidemic”, and remains as the least studied form of 
substance abuse, although research on its epidemiology, neurobiology, treatment, and 
prevention has accelerated in recent years (Howard et al., 2011). The high prevalence of 
lifetime use of inhalants is also evident in the general population of Brazil, as inhalants are 
the fourth most widely used drug (Fonseca et al., 2010). Considering these statements, the 
present study sought to investigate the role of first use of inhalants within sequencing pattern 
of first use of drugs among Brazilian university students.
Kandel (1975) and Kandel & Faust (1975) proposed a gateway model that attempts to 
explain the passage from the first contact with a drug to the first contact with a second drug. 
In this model, the user would go through four stages of involvement with psychoactive 
substances. There was no special attention to inhalants in this proposed model despite their 
high prevalence of use. At first, usually individuals use beer and wine. Then, individuals 
could use tobacco and/or strong drinks (liquor, spirits). From the second stage the person 
could go to a third stage, in which use of cannabis can happen. The gateway hypothesis 
implicitly assumes a causal chain sequence in which: (a) alcohol and/or tobacco use preceed 
cannabis use; (b) cannabis is used prior to the onset of other illegal drugs (including 
inhalants); and (c) the use of cannabis increases the likelihood of using other illegal drugs 
(Fergusson et al., 2006).
Alcohol and tobacco are indeed the first drugs that adolescents experiment with according to 
several international studies (Van Etten et al., 1997, Wagner & Anthony, 2002, Herrera-
Vazquez et al., 2004, Wells & McGee, 2008, Caris et al., 2009, Mayet et al., 2010), which 
may be due to the fact that these two drugs have the highest prevalence of use throughout 
the lifespan in most countries. However, there are a considerable number of individuals who 
experiment with cannabis before alcohol and/or tobacco depending on neighborhood (Tarter 
et al., 2006) and ethnic factors (Vaughn et al., 2008). Regarding sequence of first use of 
drugs other than alcohol and tobacco, data is more controversial (Castaldelli-Maia et al., 
2014a). In countries with a high prevalence of cannabis use, such as Germany, Ukraine and 
New Zealand, the first use of cannabis precedes the first use of drugs other than alcohol and 
tobacco (Degenhardt et al., 2010). This pattern was indeed the case for Brazilian university 
students in a previous study (Castaldelli-Maia et al., 2014b).
However, there are few studies (Ding et al., 2009; Sanchez et al., 2013) focusing on 
inhalants within drug first use sequencing pattern. In the U.S., Ding et al. (2009) found that 
inhalants are more commonly used before other illicit drugs in a large sample of inhalant 
users. Within the Brazilian university student population, the prevalence of lifetime use of 
inhalants was relatively high (24.6%) according to a survey conducted during this decade 
(Wagner et al., 2007). Based on this data of relatively high prevalence of lifetime use of 
inhalants, one can hypothesise that inhalants could be commonly used before illegal drugs, 
occupying a similar role to cannabis. Sanchez et al. (2013) analysed data from a 
representative sample of 8th to 12th grade students (middle school = 8th- 9th grade; high 
school = 10th-12th grade) from private schools (n = 5,226) in São Paulo, Brazil, to test for 
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sequencing patterns among alcohol, tobacco, cannabis and inhalants. In their study, inhalants 
were characterized as an intermediate drug class between legal (alcohol and tobacco) and 
illegal (cannabis) drugs. But this previous study (Sanchez et al., 2013) did not investigate: (i) 
the sequencing patterns involving inhalants and other important drugs to the Brazilian 
context (Castaldelli-Maia et al., 2013), such as crack/cocaine (Moreira et al., 2014), 
prescription drugs (Opaleye et al., 2014), hallucinogens (Castaldelli-Maia et al., 2012) and 
ecstasy (Remy et al., 2013), and (ii) older students from college years in private and public 
settings. Considering that adolescence is a period of experimentation with various drugs 
(Malta et al., 2010), the subsequent period (university or college years) may be of interest to 
access the sequence of experimentation of with these drugs. In a previous analysis using the 
sample of the present study, the average age of first use of each of the nine drugs analyzed in 
this study was between 15.2 and 21.2 years (Castaldelli-Maia et al., 2014b).
This study investigated the role of first use of inhalants within a drug use sequencing pattern 
in a large representative sample of Brazilian university students. It is also important to 
consider the first use of drugs other than inhalants as time-dependent variables, as they may 
have a mediating role in the sequence of drug use.
2. Methods
Data comes from an epidemiological study conducted in 27 Brazilian state capitals. The 
general objective of this epidemiological study was to evaluate the socio-demographic 
characteristics, drug use and mental health aspects of a nationally representative sample of 
university students (n=12,711). The project was previously evaluated and approved by the 
Ethics Committee for the Analysis of Research Projects at the School of Medicine of the 
University of São Paulo. Data collection was completed between May and December of 
2009.
2.1. Sample
The target population of this study were university students enrolled in undergraduate 
programs in Higher Education Institutions (HEIs), both public and private, in the 27 
Brazilian state capitals (Brazil is comprised by 27 states). The undergraduate programs can 
last from 4 to 6 years in Brazil. A random sample was stratified and recruited by unequal 
size clusters. Sampling was conducted in two stages; a sample of HEIs was selected, 
followed by the selection of classes of students was chosen from this sample. Since the size 
of the HEIs and the classes (in terms of number of universities) were not always the same, 
these conglomerates were of unequal sizes.
Since all 27 state capitals had to be covered, including public and private HEIs, sample 
stratification was carried out based on these two variables (public and private), namely, by 
capital and by type of institution, a total of 54 levels. However, this stratification was used 
only for operating purposes. At the data analysis stage, only the five administrative regions 
(including the 27 state capitals) and the two HEI types were considered for stratification, 
generating a total of 10 levels. To make the field work economically feasible, it was decided 
to select a sample of HEIs and, within each one of these, select a sample of classes: the 
primary sampling unit considered for this study was the HEI, and the secondary sampling 
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unit was the class. Thus, sampling selection was made in two stages, in which the clusters 
considered included both HEIs and student groups. Since the sizes (in relation to the number 
of students) of the HEIs and the groups are not always the same, these clusters are, in fact, of 
different sizes. Thus, in general, the sampling design consisted of a random sample, 
stratified by clusters of different sizes, selected in two stages. However, this sampling 
selection method posed a challenge because of the structure of the population under review. 
In conventional sampling, the clusters form a disconnected division, i.e., the population 
elements are related to a single cluster, which is not true for higher education. Within a HEI, 
student groups are not disconnected, and there may be an overlap between groups of 
students, since a single student can be enrolled in more than one subject. To get around this 
issue, we used the multiplicity-based sampling method, enabling the individuals to be 
included in more than one cluster. However, it was necessary to obtain information about 
the number of clusters to which the elements selected for the sample were related, for later 
use in the statistical analysis stage. At the end of the data collection, one hundred out of 114 
HEIs accepted to take part in this study (88% of the estimated size), as well as 654 student 
classes (70.6% of the estimated size), with a total participation of 12,721 college students 
throughout Brazil. Although the response rate of participation was 95.6% among the college 
students who were inside classes at the time of the interview, the final response rate for this 
study was around 72.1% when the estimated size of the college student sample was taken 
into consideration (12,721/17,651). Finally, of these students (12,721), 10 were excluded 
because they claimed to use Relevin (ficticious drug); thus, the data from 12,711 nationwide 
college students were analyzed. More details about this survey could be found in Andrade et 
al. (2012).
Part of the 12,711 individuals was excluded from the present study. Respondents older than 
40-years (n = 548) were excluded because of the high probability of memory bias. In 
addition, those with missing data on the variables of interest - age (n = 141), whether they 
used the some of the drugs tested (n = 149 (cannabis); 183 (inhalants); 228 (opioid 
analgesics); 174 (tranquilizers); 206 (ecstasy); 191 (amphetamines); 190 (cocaine); 165 
(hallucinogens)), alcohol (n = 3203) or tobacco (n = 0), those who did not answer the age of 
first use of some of the drugs tested (n = 476 (cannabis); 625 (inhalants); 670 (opioid 
analgesics); 602 (tranquilizers); 316 (ecstasy); 430 (amphetamines); 284 (cocaine); 298 
(hallucinogens); alcohol (n = 3,203) or tobacco (n = 985) - were excluded. Sample size 
varied according to the transition considered.
2.2. Measures
A structured, self-administered, and anonymous questionnaire of 98 closed questions was 
developed with an emphasis on drug use and related disorders, risky behaviours and the 
existence of psychiatric comorbidity (depressive symptoms and psychotic and nonspecific 
psychological complaints). The content of this questionnaire was based on the World Health 
Organisation research questionnaire, which was previously adapted by Andrade et al. (1997) 
and Stempliuk et al. (2005) for use with undergraduate students.
The present study used part of these data, which focused on drug use. This section was 
collected in a series of questions with multiple response options. In the first part, the 
Castaldelli-Maia et al. Page 4













students reported whether they had ever used the following drugs (“Have you ever tried 
NAME OF THE DRUG without a doctor's prescription? Answer: Yes or No”): inhalants, 
alcohol, tobacco, cannabis, cocaine, “merla” (a cocaine by-product), crack, hallucinogens, 
ketamine, ayahuasca (Santo Daime), ecstasy (3-4 methylenodyoximethamphtamine, 
MDMA), anabolic steroids, tranquilizers, prescription opioids, anticholinergics, heroin, 
amphetamines, and synthetic drugs (methamphetamines and GHB). In the second part of the 
questionnaire, we asked for the age of the initial use of each of these drugs (“How old were 
you when you first tried NAME OF THE DRUG? Answer: XX years”). For this study, 
cocaine, “merla” and crack were combined in the same group (named cocaine).
Our survey instrument included questions that asked all respondents about the use of 
'inhalants or solvents’ giving as examples: “loló”, glue, paint thinner, benzene, enamel, 
gasoline, and “lança-perfume”. All these examples of inhalants or solvents cover the vast 
majority of types of substances of this class of drugs used in Brazil (Mesquita et al., 1998; 
Hynes-Dowell et al., 2011; Sanchez et al., 2013; Silva-Oliveira et al., 2014)
2.3. Statistical analysis
• Time-dependent variables—Because the aim of this study was to assess the whether 
the transition from the first use of one drug to the subsequent use of another drug occurred 
or not – always involving inhalants in one of the two roles – these comparisons were always 
performed between users and non- users groups (e.g., investigating the transition from 
inhalants to cocaine – we tested inhalants users versus inhalants nonusers - these groups 
were defined based on three options available in these two parts of the following question: if 
the subject had already used inhalants, if the subject had already used cocaine, and whether 
the subject had used the inhalants before, in the same year, or after cocaine. Inhalants users – 
if s/he just used cannabis or cocaine after inhalants. Inhalants non-users – if s/he did not use 
both drugs, or used just cocaine, or inhalants before cocaine. If s/he used both in the same 
year, s/he was classified as a ‘drug seeker'). Users and non-users were assembled for each 
transition to perform analyses of the transitions from the first use of a drug to the first use of 
another drug. Analyses focused on transitions of first use of inhalants with first use of 
alcohol, amphetamines, cannabis, cocaine, ecstasy, hallucinogens, prescription opioids, 
tobacco, and tranquilizers. Figure 1 depicts the division between users and non-users. The 
drug seekers were considered drug users with the response (the use of the subsequent drug 
tested in the model) of event censored. With this we have tried to avoid loss of important 
data on other socio-demographic variables included in the regression models.
• Time-dependent covariates—Drugs other than the pair of drugs tested in each 
survival model were included as time-varying dependent covariates in all models. (e.g. in 
the model testing the the pathway from cannabis to inhalants – if the individual first used 
alcohol after first using cannabis and before first trying inhalants, s/he was classified as 
alcohol user in the alcohol use time dependent variable of this model).
All analyses were performed using the survey settings commands with weights, strata and 
primary sampling units. The analysis of the survey data complied with the following 
characteristics of the sampling plan: (a) a complex sample, (b) the use of stratification, (c) 
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clustering and (d) dissimilar selection probabilities. Survival analysis methods were used to 
compare between one type of drug users and non-users the cumulative prevalence of other 
type of drug use. We chose to use Cox Regression Survival Models (Cox, 1972), following 
an important framework (Singer & Willett, 1994). We used the statistical package STATA 
version 11 to run the models with time dependent covariates (as described above) and non-
time dependent covariates (these 14 sociodemographic covariates are presented in Table 1) 
adjustment. The Kaplan-Meier curves were plotted without any adjustment for other 
variables, and without the exclusion of individuals with more than 40-years. We chose to 
use a link test to test for proportional-hazards assumption (Cleves et al., 2010). These re-
estimation tests were carried out to test for the validity of each Cox model. It searches for 
variables to add to the model. Under the assumption that the Cox model is correctly 
specified, the added variables will add little or no explanatory power, so it tests that these 
variables are insignificant. The Cox model reaches validity with p > 0.05 in this link test. 
Cox models with p < 0.05 in link test were not considered for discussion.
3. Results
Table 1 depicts the socio-demographic information of the sample. Table 2 presents the 
results of the transitions analyzed and Figure 2 highlights all the transitions that did not 
violate the Linktest of proportional hazard-assumptions (LHPA) and could be taken into 
account. Figure 3 depicts all Kaplan Meier curves of the transitions which had significant 
differences that did not violate the LHPA. Overall, the first use of inhalants was subsequent 
to first use of alcohol (n = 1,181), tobacco (n = 655) and prescription opioids (n = 64), and 
preceded the subsequent first use of prescription opioids (n = 181), cannabis (n = 409), 
cocaine (n = 271), tranquilizers (n = 165) and amphetamines (n = 363).
3.1. Transitions from first use of inhalants to first use of other drugs
Seven of nine models did not violate the LHPA. Within the valid models, the cumulative 
prevalence of first use of amphetamines (aHR = 2.59, 95% CI = 1.65-4.07, p < 0.001), 
cannabis (aHR = 1.56, 95% CI = 1.26-1.93, p < 0.001), cocaine (aHR = 4.33, 95% CI = 
3.08-6.09, p < 0.001), prescription opioids (aHR = 29.39, 95% CI = 7.17-120.54, p < 0.01) 
and tranquilizers (aHR = 2.10, 95% CI = 1.05-4.18, p < 0.05) were significantly higher 
among those that had first initiated inhalant use as compared to inhalants non-users. 
Regarding gender, there was higher cumulative prevalence of alcohol and cannabis first use 
among men as compared to women (aHR = 0.70, 95%CI = 0.53-0.93, p < 0.05, and aHR = 
0.56, 95%CI = 0.39-0.80, p < 0.01, respectively), adjusting for previous use of inhalants. 
However, regarding amphetamine and tranquilizer first use, an opposite situation occurred. 
The cumulative prevalence of first use in these cases were higher among women compared 
to men (aHR = 5.51, 95%CI = 3.72-8.15, p < 0.001, and aHR = 2.28, 95%CI = 1.48-3.50, p 
< 0.001, respectively), adjusting for previous use of inhalants. There were no gender 
differences in regards to cocaine, prescription opioid, and tobacco first use.
3.2. Transitions from first use of other drugs to first use of inhalants
All models did not violate the LHPA. The cumulative prevalence of first use of inhalants 
was significantly higher among alcohol (aHR = 1.41, 95% CI = 1.09-1.81, p < 0.01), 
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prescription opioids (aHR = 3.51, 95% CI = 1.14-10.82, p < 0.05) and tobacco (aHR = 2.70, 
95%CI = 1.92-3.79, p < 0.001) first users as compared to non-users of these drugs. In 
addition, the cumulative prevalence of first use of inhalants was significantly lower in 
cocaine (aHR = 0.06, 95%CI = 0.01-0.23, p < 0.001) first users as compared to cocaine non-
users. Within all the transitions, there was a higher cumulative prevalence of inhalant first 
use among men as compared to women, adjusting for other drugs previous use.
4. Discussion
The main aim of the present study was to conduct an analysis of the role of first use of 
inhalants within the sequence of first drug use, and we found that it was preceded by the first 
use of alcohol, tobacco and prescription opioids. However, the first use of inhalants 
preceded the first use of amphetamines, cannabis, cocaine, prescription opioids and 
tranquilizers. These findings place inhalants into the position that is typically ascribed to 
cannabis, as its first use is more common after the first use of legal drugs and before the first 
use of illegal drugs. Additionally, cannabis first use did not precede inhalants first use; 
rather, the opposite pattern was evident.
A global debate on the validity of studying the transition of various drug use (Van Etten et 
al., 1997, Wagner & Anthony, 2002, Herrera-Vazquez et al., 2004, Wells & McGee, 2008, 
Caris et al., 2009, Mayet et al., 2010) was revived due to the results of a study investigating 
epigenetic alterations related to drug experimentation in laboratory animals (Levine et al., 
2011). Pre-treatment of mice with nicotine increased their responses to cocaine, as assessed 
by addiction-related behaviours and synaptic plasticity in the striatum, a brain region critical 
for addiction-related rewards. The responses to cocaine were altered only when nicotine was 
administered first, and then nicotine and cocaine were administered concurrently. Reversing 
the order of the drug administration was ineffective, as cocaine had no effect on nicotine-
induced behaviours and synaptic plasticity (Levine et al., 2011). There is also fresh 
epidemiologic data on this field. A recent multicentre study revealed that the sequence of 
drug experimentation may be linked to particular issues related to alcohol and drug use in a 
specific country (Degenhardt et al., 2010) and that violations of the classical sequence of 
drug experimentation (i.e., alcohol/tobacco → cannabis → other drugs) seem to be more 
common in countries with low lifetime use of alcohol, tobacco, and cannabis. Thus, it is 
important to study first use sequencing patterns in other less developed settings, such as 
Brazil, where there is different prevalence of lifetime drug use (e.g., higher levels of lifetime 
prevalence of inhalant use).
Ding et al. (2009) studied the position of inhalants in the sequence of drug use in U.S. using 
data from the 2003 National Survey on Drug Use and Health (NSDUH). The age of first 
inhalant use was compared with the age of onset of other drug use among 6,466 inhalant 
users who also used at least one of 14 other drugs. The findings indicated that only 4.2% of 
multiple drug users had used inhalants prior to using other drugs, in particular, alcohol, 
tobacco, and cannabis. Thus, the theory that first use of inhalants is more common before 
the first use of illegal drugs was not supported in this study. Comparing this study (Ding et 
al., 2009) design with the current one, we have found many differences. In the present study, 
we used survival analysis methods to compare drug users and non-users while taking into 
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account the cumulative prevalence of other drug use across time. We chose to use Cox 
regression survival models following an important framework (Singer & Willet, 1994, 
Wagner & Anthony, 2002). Another explanation for the differences between the two studies 
could be trends over time. That is, inhalants can be more commonly used in 2009 in Brazil 
as compared to U.S. in 2003. However, recent U.S. data shows that 17% of youths initiated 
inhalants during middle school (Ober et al., 2013) – a considerable high rate of initiation.
Our findings are in line with those from Sanchez et al. (2013) in their study with a younger 
sample of private school high- and middle-school students in São Paulo, Brazil. We also 
found that inhalants use preceded the cannabis use. In addition to that transition, our study 
expand this role of inhalant use - preceding the use of other illicit drugs – in a large and 
representative sample of Brazilian urban university students. Considering that, a number of 
classical statements should be reconsidered in light of findings such that in our country. 
First, if there is a more common sequence of drug experimentation, then inhalant use should 
be placed in the same step of (or even before) cannabis - after legal drug use and before 
illegal drug use. There are few studies regarding drug transitions that take the position of 
inhalants in this sequence into account.
The first use of inhalants preceded the first use of amphetamines, cannabis, cocaine, 
prescription opioids and tranquilizers. However, the magnitude of the association between 
prior use of inhalants and subsequent use of these drugs varied a lot, which leads us to 
believe that the chance of using some drugs may be greater than others after using inhalants. 
Surely this is the case of prescription opioids and cocaine, with the highest adjusted hazard 
ratios (aHR). However, the absolute number of individuals that first used a drug after using 
inhalants was highest for cannabis and amphetamines, which should also call for the 
attention of police makers.
The transition to/from inhalants use seems to be a confounding factor in the association 
between gender and drug use. In all transitions tested from other drugs first use to inhalants 
first use, there was higher prevalence of inhalants first use in men compared to women, what 
is in line with previous findings of the prevalence of inhalants use in this sample (Andrade et 
al., 2012). Regarding the use of other drugs, there was higher cumulative prevalence of 
alcohol and cannabis first use among men, and of amphetamines and tranquilizers first use 
among women, that is also in line with previous findings (Andrade et al., 2012). However, 
the present study did not confirm higher prevalence of tobacco and cocaine first use among 
men, and first use of tranquilizers among women, as previously found in this sample 
(Andrade et al., 2012). This leads us to believe that the adjusting for previous inhalant first 
use made the gender differences in cocaine and tranquilizers first use disappear, positing 
first use of inhalants as a confounding factor. Other studies could investigate the role of 
inhalants previous use as a confounding factor for associations between gender and drug 
use.
There is a consensus among the few studies regarding inhalants from across all of the areas 
in the addiction field (Howard et al., 2011, Konghom et al., 2010), and our results support 
the implication that more attention to inhalant use and in its consequences and correlates are 
needed, especially in Brazil. Nonnemaker et al. (2011) suggested a strong relationship 
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between inhalant use, other problem behaviors and sensation-seeking. These results 
highlight the need to intervene early with youths who are at risk of or just beginning to 
engage in inhalant use, given that low-frequency inhalant users report predominately 
hedonic experiences during inhalant intoxication that are not aversive (Garland & Howard, 
2010). Even non-persistent use of inhalants is associated with a greater risk for nonmedical 
opioid and stimulant use and is a strong predictor of non-persistent opioid and stimulant use 
(Nakawaki & Crano, 2012).
4.1. Limitations
An important limitation of this study is the recall bias, which is inherent in cross-sectional 
studies (Raphael, 1987). In addition, it is also difficult to extrapolate from data obtained 
from university students to the Brazilian general population. College students in this country 
are not representative of the general population as only 13.9% of young adults have access 
to higher education. Almost 50% of university students study in private institutions, which 
sets them apart from the general population. However, we did use a representative sample 
from all of the Brazilian capitals, thus providing balanced data from this large country, with 
various social, cultural and economic differences (Victora et al., 2010, Parayba & Veras, 
2008). In addition, 8 of 36 transitions tested violated the linktest for the proportional hazard 
assumption LPHA), which implies the absence of important transitions (i.e., between 
cannabis and tobacco).
Another limitation is that if a respondent did not provide the age of first use of a drug, we 
could not use this individual data to perform any analysis of a transition that involved this 
drug. In view of the large number of people who did not remember at least one of the ages 
of experimenting with some of the drugs, we decided to carry out a comparative analysis 
between individuals who remembered all the ages of experimentation with drugs and those 
who did not remember at least one of the ages (missing group). To this end, we analyzed the 
sub-sample of those individuals who used drugs at least 1 drug of all the following three 
groups: (i) alcohol and/or tobacco; (ii) marijuana and/or inhalants; (iii) cocaine and/or 
hallucinogens and/or ecstasy and/or amphetamine and/or prescription opioids and/or 
tranquilizers. From this analysis (Appendix 1), individuals who: were older; had a religion; 
not practiced their religion; used hallucinogens; used ketamine; did not use tranquilizers; did 
not use barbiturates; and did not use codeine syrup; were associated with the missing group. 
Therefore, one should take care when extrapolating our findings to these sub-populations. 
Future analyses on first drug use sequencing patterns involving hallucinogens and 
tranquilizers would be interesting to better evaluate these transitions.
4.2. Conclusion
This study highlights the need to intervene early with youths who are at risk of or just 
beginning to engage in inhalant use, since this class of drugs seems to be the first to be 
experimented with in our sample. There is also a call for attention to individuals who have 
already first used inhalants because of their higher chance to experiment with other drugs 
such as cannabis, cocaine, and prescription drugs. It was also interesting to find that 
cannabis were subsequent compared to inhalants within first use sequencing pattern. All 
these findings show an in-transition culture of drug use among young adults in Brazil.
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Appendix
Appendix 1
Results of logistic regression comparing individuals used at least 3 drugs and were reminded 
of all the ages of exeprimentation of these drugs and those who any age of experimentation 
was missing among Brazilian university students, 2009.
Variable aOR SE p [95% CI]
Age 1.92 0.51 0.018 1.12 3.28
Gender 1.01 0.23 0.936 0.64 1.61
Type of religion 1.27 0.11 0.008 1.06 1.52
Praticing the religion 0.64 0.12 0.023 0.44 0.94
Scholarity of the head of the family 0.81 0.12 0.177 0.60 1.09
Socioeconomic status 1.04 0.03 0.238 0.97 1.11
Ethnic group 0.69 0.16 0.125 0.43 1.10
Civil status 0.78 0.20 0.364 0.46 1.32
Children 0.56 0.27 0.250 0.21 1.50
Currently working 1.22 0.17 0.166 0.91 1.63
Driver license 0.56 0.16 0.056 0.31 1.01
University course area 1.18 0.17 0.244 0.88 1.58
Semester of the course 0.96 0.09 0.735 0.79 1.17
All-day course 0.98 0.31 0.954 0.51 1.86
Happy with the course choice 0.81 0.33 0.607 0.36 1.82
Alcohol use 0.90 0.86 0.918 0.13 6.06
Tobacco use 0.83 0.15 0.330 0.57 1.20
Cannabis use 1.19 0.38 0.591 0.62 2.27
Inhalants use 0.99 0.33 0.979 0.50 1.95
Cocaine use 1.23 0.38 0.498 0.66 2.30
Hallucinogens Use 2.59 1.20 0.044 1.02 6.55
Ketamine use 20.85 25.32 0.014 1.86 233.25
Ayahuasca use 1.49 0.85 0.486 0.47 4.65
Ecstasy use 0.62 0.23 0.217 0.29 1.32
Steroids use 0.59 0.27 0.259 0.24 1.46
Tranquilizers use 0.54 0.11 0.005 0.35 0.83
Sedative/Barbiturates use 0.17 0.13 0.028 0.03 0.82
Opioid analgesics use 0.45 0.19 0.070 0.18 1.06
Codein syrup use 0.05 0.04 0.002 0.01 0.33
Anticholinergics use 2.00 1.83 0.452 0.32 1.23
Heroin use 6.63 11.47 0.277 0.21 206.65
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Variable aOR SE p [95% CI]
Amphetamine use 0.69 0.28 0.391 0.30 1.59
Synthetic drugs use 1.97 1.93 0.490 0.28 1.39
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Fluxogram presenting the division of the individuals between users and non-users, among 
Braziian university students of the 27 states capitals, 2009.
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The scheme highlights all the transitions that did not violate the linktest of proportional 
hazard-assumptions (LHPA) and could be taked into account (see details in Table 2). The 
arrows were drawn every time the Cox survival regression model reached significance* 
(p<0.05). If the arrow is blue, the cumulative prevalence of first use of the drug in the 
lefthead of the arrow was higher in users than non-users of the drug in the righthead of the 
arrow (aHR > 1). If the arrow is red, the cumulative prevalence of first use of the drug in the 
lefthead of the arrow was lower in users than non-users of the drug in the righthead of the 
arrow (aHR < 1).
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Kaplan-Meier curves of all transitions which involved inhalants and did not violate LHPA.
Castaldelli-Maia et al. Page 16

























Castaldelli-Maia et al. Page 17
Table 1
Sociodemographic data (14 variates included in the Cox survival models) of Brazilian university students from 
27 capitals, 2009.
Variable % 95%CI SE
Gender
        Female 56.87 53.67-60.00 0.01
        Male 43.13 40.00-46.33 0.01
Age*
        < 22 years 38.93 25.69-54.04 0.07
        > 21 years 61.07 45096-74.31 0.07
Religion
        None 14.85 12.25-17.90 0.01
        Catholic 50.00 45.79-54.22 0.02
        Spiritualist 8.90 7.40-10.68 0.01
        Umbanda/Candomble 1.77 0.77-4.04 0.01
        Jew 0.67 0.37-1.20 0.01
        Reformed/Evangelical 17.42 14.17-21.24 0.01
        Buddhist/Hindu 0.64 0.40-1.02 0.01
        Santo Daime/Vegetal Union 0.20 0.01-0.44 0.01
        Other 4.97 3.39-7.24 0.01
Practice of the religion
        Special occasions only 35.26 33.27-37.30 0.01
        Montly or more 45.71 43.26-48.19 0.01
        No 18.12 16.16-20.26 0.01
Socioeconomic status*
        Low 0.01 0.01-0.29 0.01
        Low-average 1.75 0.01-2.37 0.01
        Average 25.23 21.64-29.19 0.01
        High-average 62.84 58.85-66.66 0.01
        High 10.09 7.76-13.02 0.01
Head of the family education
        Zero 7.06 5.45-9.10 0.01
        Up to 4 years 7.60 6.01-9.57 0.01
        5-8 years 6.02 4.69-7.69 0.01
        9-11 years 35.10 31.66-38.71 0.01
        12 years or more 42.44 37.39-47.66 0.02
Ethnic group
        Caucasian 62.27 66.05-70.53 0.01
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Variable % 95%CI SE
        African-American 6.50 5.31-7.94 0.01
        Mulato 24.71 21.44-28.31 0.01
        Oriental 2.45 1.41-4.22 0.01
        Indian 0.11 0.57-2.11 0.01
        Other** 2.96 2.37-3.71 0.01
Marital status
        Single 75.68 63.89-84.56 0.05
        Married/Living together 20.10 13.50-28.84 0.03
        Separated/Divorced 3.57 2.03-6.21 0.01
        Widow 0.65 0.14-2.87 0.01
Children
        Yes 19.78 11.82-31.19 0.04
        No 79.56 68.38-87.51 0.04
Employment
        No 39.65 34.95-44.54 0.02
        Up to 20h/week 17.85 15.12-20.94 0.01
        >20h/week 41.85 35.50-48.49 0.03
Driver License
        Yes 61.11 57.62-64.49 0.01
        No 38.23 34.97-41.60 0.01
Area of undergraduate studies
        Biological/Health 17.67 10.87- 27.40 0.04
        Mathematics 17.01 11.60-24.25 0.03
        Humanities 65.33 55.96-73.64 0.04
Current year in college/university***
        First 28.67 21.83-36.65 0.03
        Second 26.42 18.19-36.70 0.04
        Third 17.00 11.22-24.92 0.03
        Fourth 14.33 9.93-20.23 0.02
        Fifth 9.64 3.75-22.61 0.04
        Sixth 2.13 1.37-3.31 0.01
All-day classes
        Yes 15.05 8.27-25.82 0.04
        No 84.95 74.18-91.73 0.04
Happy with the undergraduate choice
        Yes 92.03 88.58- 94.50 0.01
        No 7.53 5.20-10.80 0.01
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*
Included in the Cox survival regression model as continuous measures
**
The person does not includ himself/herself within in none of the ethnic groups listed above.
***We did not ask whether or not students had failed in courses during their studies.
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